Stock Price Quote

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal
BSE1801.5071.4 (+4.13 %)
PREV CLOSE ( ) 1801.50
OPEN PRICE ( ) 1739.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 12461
TODAY'S LOW / HIGH ( )1731.00 1830.00
52 WK LOW / HIGH ( )1115.15 1903.85
NSE1799.9068.4 (+3.95 %)
PREV CLOSE( ) 1799.90
OPEN PRICE ( ) 1740.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1799.90 (104)
VOLUME 381731
TODAY'S LOW / HIGH( ) 1725.05 1835.00
52 WK LOW / HIGH ( )1111.6 1904.45
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 31-12 1979
Management Info
Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director
Registered Office

Address Ajanta House,Charkop ,Kandivali (W),
Mumbai,
Maharashtra-400067

Phone 022-66061000

Email legal.info@ajantapharma.com

Website www.ajantapharma.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

27Sep Ajanta Pharma informs about loss of sh
Pursuant to Regulation 39(3) and other applicable regulations of SEBI Li..
14Sep Clarification sought from Ajanta Phar
The Exchange has sought clarification from Ajanta Pharma Ltd on Septembe..
04Sep Ajanta Pharma informs about newspaper
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Re..
31Aug BHEL, Ajanta Pharma and DCX Systems to
Bharat Heavy Electricals (BHEL) has secured the order from NTPC (a Govt...
31Aug Ajanta Pharma zooms on getting USFDA’s
Ajanta Pharma is currently trading at Rs. 1782.60, up by 54.10 points or..

Financials

in Millions
QTR Jun 23 ANNUAL 23
Net Profit2120.45587.19999999999
Gross Profit 2753.7 6998.49999999999
Operating Profit 3083.68320.29999999999
Net Sales 10145.834112.7

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  23159.10 (3.44%)
M.Cap ( in Cr)49211.47
Dr. Reddy's Lab (BSE)
peergroup  5586.75 (2.97%)
M.Cap ( in Cr)93178.48
Sanofi India (BSE)
peergroup  7206.50 (2.09%)
M.Cap ( in Cr)16597.02
Divi's Lab (BSE)
peergroup  3764.75 (2.75%)
M.Cap ( in Cr)99942.28
Alkem Laboratories (BSE)
peergroup  3607.65 (2.41%)
M.Cap ( in Cr)43134.87

Shareholding Pattern

NON-INSTITUTION 7.79%
PROMOTERS 66.21%
MUTUAL FUNDS/UTI 13.07%
FI/BANKS/INSURANCE 1.64%
GOVERNMENT 0%
FII 0%

About Ajanta Pharma Ltd.

Ajanta Pharma Ltd. was incorporated in the year 1979. Its today's share price is 1801.5. Its current market capitalisation stands at Rs 22683.71 Cr. In the latest quarter, company has reported Gross Sales of Rs. 34686.6 Cr and Total Income of Rs.35440.2 Cr. The company's management includes Gaurang Shah, Anjana Grewal, KH Viswanathan, Rajesh M Agrawal, Madhusudan B Agrawal, Prabhakar Dalal, Chandrakant M Khetan, Yogesh M Agrawal, Mannalal B Agrawal.

It is listed on the BSE with a BSE Code of 532331 , NSE with an NSE Symbol of AJANTPHARM and ISIN of INE031B01049. It's Registered office is at Ajanta House,Charkop ,Kandivali (W)Mumbai-400067, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, Kapoor & Parekh Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.